Novel cyclic peptides having VLA-4 adhesion inhibiting activity, and their application as therapeutic agents for inflammatory disease, for example allergic inflammatory disease, or hepatitis. Cyclic peptides represented by formula (I)where A and F may be the same or different, and are both selected from L- or D-form Cys, homo-Cys, Pen and Mpr, or both from the group comprising Asp, Glu, Aad, Dpr, Dab and Orn, B is selected from L-or D-form Ala, Ala(t-Bu), Val, Leu, Ile, aIle, Abu, Nle, Nva, Tle, Cha, Chg, Phe, Phg, Trp, Ala(3-Bzt), Ala(1-Naph), Ala(2-Naph), Ala(2-Pyr), Ala(2-Qui), His, Thi, Ala(4-Thz), 2-Abz, Pro, homo-Pro and Tic, C is selected from L-form Asp analogues, Gle analogues, Aad analogues, Asn analogues, Gln analogues, Ser, Ser(OMe), homo-Ser, Dpr, Dab, Orn, Met, Met)O), Met(O2), aIle, Nle, Nva, Chg, Phg, Tyr and Tle, D is selected from L- or D-form Tyr, Ser, homo-Ser, Leu, Ile, AIle, Nle, Nva, Chg, Cha, Val, Ala(t-Bu), Abu, Tle, Ala, Phg, homo-Phe, Phe, Ala(2-Naph), Ala(2-Pyr), Ala(3-Bzt), Ala(1-Naph), Ala(2-Qui), Thi, Ala(4-Thz), 2-Abz, Trp and His, E is selected from L- or D-form Leu, Ile, aIle, Nle, Nva, Chg, Cha, Tle, Phg, homo-Phe, Ala(2-Naph), Ala(2-Pyr), Ala(3-Bzt, Ala(1-Naph), Ala(2-Qui), Thi, Ala(4-Thz), 2-Abz and His, G represents a disulphide bond or amide bond, R1 represents hydrogen or an acyl group, and R2 is hydrogen or an alkyl group, or salts thereof, and to their use in treating inflammatory diseases.